However, in this study, the GvHD patients had lower bIFI rates than the AML/MDS group, probably because the GVHD patients who enrolled to the study all received AFP, and they received it for a longer period of time compared to the AML/MDS patients. This evidence concerns the gene AFP and acute myeloid leukemia.